HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Krystal Biotech (NASDAQ:KRYS) and maintained a $200 price target.

August 05, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Krystal Biotech and maintained a $200 price target.
The reiteration of a Buy rating and the maintenance of a $200 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100